Thanks for everybody. joining Hello, today. us
XXXX our will respond comments, provide positive XXXX we to prepared questions. and XXXX quite early we and After our this which insights recap results, our progress. will call, into were priorities some During
of in advance. sent address to prepared those you questions comments. We attempted of Some questions our in many
is exciting for and It Amarin. time busy
making the well broad position to Amarin's year vote approval reduction VASCEPA improving unanimous VASCEPA future. regarding and consistent XX-X new for and expanded therapy. seven by our In are XXXX, the we clearly the in its VASCEPA pursuant from hearing FDA are XXXX professionals us we and and demonstrated results clinical outweighed needing this AdCom cardiovascular robust by in for patient and for feedback which care. the outcome patients indication, are healthcare and risk a results received progress shifting we're now the and with clinical We enthusiastic study encouraged of unanimous role the vote. uncommon The reflects AdCom this paradigm following completion votes REDUCE-IT benefits, risks of by
through volume an on in first We of Typically, realized predominantly increased revenue revenues would sold in prescriptions achievements. of list our normalized United increase XXXX, States, VASCEPA reflecting an XX% the over growth be VASCEPA. increase in XX% in of
by enormity the FDA’s of XXXX, indication VASCEPA. of of the growth to For for this approval is of and the the Amarin care patient eclipsed importance expanded
And to cost for contributed to should heart Europe MedStar, XX broaden attacks. save our helping VASCEPA analyses, that conclude money for effective, review as is management; most society Medicines market VASCEPA addition, cardiovascular use occurrence filed the including cost further high in and and events, as than reach, clinical sales on-boarded partner’s trial the sales for risk to eight a option of sales treatment Canada; in and Canadian of European had accepted an In of analyses the a such hired for not as of VASCEPA. to reduce VASCEPA includes results reduction other Such the reporting witnessed by cardiovascular VASCEPA VASCEPA observed issuance for hundreds by approval to representatives scenarios while recognized stroke any scientific by product VASCEPA to pharmacoeconomic market filing reference new our multiple bolstering Agency; centralized medical we generalizable societies. publications approval major filing our presentations; recognition that and being supported in becoming that
of outstanding cite an additional results. accomplishments XXXX execution Clearly, many could XXXX. was in Amarin I and year
We indication. VASCEPA the VASCEPA risk a proven are commercial let's now focused discussion the this on new Accordingly, drug new is for success of XXXX. represents and to our new shift class VASCEPA of indication. preventative with only launch the of therapy. reduction first cardiovascular its
to launch or Such which the in that demonstrate VASCEPA this magnified the of terminated their products benefits for have Our reflects exceed VASCEPA. cardiovascular competitors risks is a of the of outcome of potential products. completed backdrop new uniqueness indication all studies uniqueness by failed such that
a patients their with are press issued Today's factors, Of of this It was label risk course, is healthcare the we in option decrease of events important ''. at-risk and this release the drug issued pertaining VASCEPA indication, the regarding for corresponding further treated we immediately treatment in risks are disease, professionals significant and new help only and and in press can will that VASCEPA approval give be VASCEPA. provides a which stroke indication, that to approval new gratifying after VASCEPA including every triglycerides new FDA for patients Not results elevated approved for diabetes, approval, adjunctive FDA approval which that FDA '' cardiovascular with first stated, heart that as December pleased to an should other this it the pleased release. discretion FDA
tremendous using and demonstrated robust. of VASCEPA is The benefit
for professionals Our on of who can VASCEPA. launch this these healthcare from access planned. expanded far, Thus care emphasizes indication our managed includes benefit affordable VASCEPA education progressing securing VASCEPA of and all of regarding for is benefits patients for launch focus commercial as
care pharmacists professionals, further regarding feedback We positive improvements some managed of examples healthcare coverage. are other to and hearing physicians, witnessing while early positive from VASCEPA
in been are risk the shown reduction Our This have to they existing largest statins. been by addition helpful enough. but to has therapy. cardiovascular to do messaging VASCEPA XX%. XX% XX% shown statin Statins lower therapy, risk risk another reduction the don't as that reflects cardiovascular such by statins, shown beyond to is lower risk from approximately
XX% in statin respectively reductions and X% relative treated demonstrated acetamide risk For patients. example, PCSKX inhibitors approximately and have
cholesterol treatment lowering improving wish patient cholesterol VASCEPA, care products with clinical and a in REDUCE-IT forums. scientific scientific crowded activity provides cholesterol the the VASCEPA care. include addressing compete VASCEPA. We evaluation knowledge in With Strong not of will new in does to to presentation such management. LDL other congresses beyond medical of us to success management. active intend increasingly we unmet led need medical all and results continue well of the and option field XXXX are detailed study. has We patient of be at Such further
Amarin or we have been persistent Scientific related in we conjunction presentations on presenters scheduled that VASCEPA closer This been plan webcast scientific accepted includes VASCEPA cardiovascular Cardiology example, the American one of has to many Annual be of for to accepted. March College as of this these Sessions that get risks the medical For upcoming that to with at March, XXXX In eight their a late presentation conference, comments from conference. as will findings. made Details regarding late breaker. webcast sponsored regarding
the such institutions study as invited presentations data medical grand study. education sponsoring new we're rounds leading and REDUCE-IT parallel medical principal regarding in at lectures And for active also forums, scientific regarding the of also making REDUCE-IT various investigator the remains known In unprecedented with results VASCEPA. at the forms of
force, professionals means our including multi-dimensional promotion outreach various opportunity electronic sales commercial healthcare scientific of have advertisement. increasing forms not many means, do are the all VASCEPA our to direct forums. of to we via attend and Unfortunately, Accordingly,
doubling sales our the Regarding States, to we in now are force United close size. its
is promotional representatives As activities dollar XXX by of previously we believe sales S. a supported our U. described, VASCEPA make that positioned other a multibillion sales force to brand.
the We sales well. newly been December, and believes Our A trained should January February. filled. positions as have point, soon. field waves be sales sales all team XXX targeted small representatives nearly enthusiastically the in number new of representative They training. of At still representatives undergoing sales hired are this hired this and during in
some is members succeed intelligence, and nature don't our of of team. are sales of the we hiring, need to As Overall, and replaced. the attitudes, impressed be experience the with passion people
VASCEPA is hired materials for our the We In new the all we representatives new in our year did for not regarding promotional a It of States or be sales United sales the to representatives our for progress representatives judge early to commencing for our hired part progress its too training sales sales sales wait the in launch launch. of It highly VASCEPA. become representatives of for better of messaging before conducted and of launch new sales January, new typically the indication. newly early to the takes productive.
possible this is occur that may VASCEPA, with faster. it Although
to did sales many hearing and these more our that whom are comment come VASCEPA their from are to clinical anecdotes to positions more VASCEPA the unprecedented VASCEPA’s prior tenured of previously representatives, not of many recently and hired VASCEPA taking positive directly promote We are aware results. our anecdotes and FDA responding related receptive who prescribers pursuant approval. both from of we who Other patients now anecdotes are
and As the doctors that does purposes. of they rather aside, in and for use fasting that cardiovascular triglycerides, us impressed label. label can between practice doctors label day, it required that type not diabetic They the label than language an FDA doesn't management the reference definitions set type such as are like patients approved the which trial the that They they believe of VASCEPA. medical breadth for with any establish reflects appreciate X to their have that for X help terminology, non-fasting they expressed distinguish many clinical cholesterol or Many this doesn't with and used it every target disease patients. LDL
patients. meeting, physicians It regarding doctors are modern they States. therapy be the physicians proud across themselves take in invite. I it see prescribe to and This most the They heard we thrilling with we that of results to these number and our era could fortunately, were statin VASCEPA. training XS, efforts past who the as these want programs study was VASCEPA repeatedly Many studies educational results weekend, that doctors peer-to-peer to are for their clinical United and completed the preventative the bringing to standard as the regarding select will care. cardiovascular which of Throughout that conducted of program part of important we made for to REDUCE-IT of two most referring limited regarding excitement the the ranked this they conduct care doctors energy
you and healthcare see to Unless programs won't won't regarding speaker see you're these a professional, professionals sent communication electronic VASCEPA. healthcare you
VASCEPA television. you've However, many we of promotion seen that that commented began have recently you of on
are a statin such featuring that unbranded risks. of that ago a that risk to we tolerated exists addressing therapies generation awareness been campaign TV month The viewers maximally therapy. be addition, In campaign reminds spots not shown intended to earlier beyond raise have in launched persistent effective the
easier been to for than example, before results. with many are, X This as successful may roughly REDUCE-IT There justify fibrates times with treated VASCEPA. have being imbalance patients
effective However, products fenofibrates should benefit today, other of fenofibrates and given the that to multiple cardiovascular we benefit, therapy. all mixtures, on is regarding The cardiovascular consisting look to top same demonstrate failure years. therapy remind success for of and demonstrate VASCEPA, earlier and the studies beyond products generation healthcare of which of statin past failed professionals have to Omega two true X of they the including proven in failed seek consumers
is new the ad our does developed names that Drug promotion promotional by cardiovascular currently risk effects. that The mention ad and FDA can ties easily means have targeted unbranded we is use, to without its from say TV VASCEPA not I an of that under future Prescription Separately, that Promotion. for name, review it be review. VASCEPA Office messaging unbranded, directly more FDA's TV campaign reduction VASCEPA launched promotion such by When television
advertising. support with be lowering time to mid-XXXX. time intend we risk, review expect the We launch references such in name At advertising, our in branded to VASCEPA of refers to our frequency to advertisements by increase that direct-to-consumer which of and both cardiovascular completed
a We team. among be significant by in might benefit awareness VASCEPA professionals who not Amarin otherwise who anticipate are that branded raising direct-to-consumer factor sales promotion and people healthcare from VASCEPA will upon called
inflection further prescription to meaningful of launch the VASCEPA consumer in prior anticipate growth. we branded is promotions, growth anticipated program to prescriptions DTC upward such provide such While in
good. Regarding overall, managed for coverage care is coverage VASCEPA,
in it. those for to were restrictions. decided the every Managed of were We for expanded the payers XXXX changes before improve At favorable. coverage mid-December. approval VASCEPA in of at beginning label the with Such aggregate of are start managed in care coverage there exceeded plans by year coverage. working year, are expanded with FDA start care Changes changes the VASCEPA of
to benefit Following label pharmacoeconomic of FDA which VASCEPA, analysis team interacting of FDA of they our care managed affairs recommend team the drug the substitute. approval payers VASCEPA, this approval to medical the and use our clinical for without and of the appreciate guidelines have medical of ensure expanded that with societies, multiple been VASCEPA
payers restrictions have Blue Carolina Cross North to that weeks, VASCEPA plans and Michigan, removing of more we recent Blue including learned In coverage, prior Shield Arkansas.
confident that move coverage additional to We of are expand VASCEPA. will payers
because this educational right the of improvement is initiatives it our do. Some further with because of should occur thing and payers to
likely be The physicians improvement class physicians insurance. powerful broadly Some is that of therapy this and to regard. patients are occur of this new this care voices in of and preventative by insist patients covered because
coverage for calendar particularly patients can tricky year. Insurance part early a the be in of
coverage the year part year plans. deductibles drugs. of beginning of provisions individual insurance This of Such are are was due under the or the beginning various that to of independent deductibles insurance coverage insurance
a result for creating seasonal in As discussed prior filling years, prescriptions, of in effect. often beginning year deductibles their going patients these the
XXXX, as and this this seeing are impact at expected we of start again As the year. guided
we seeing physicians the continue new to where should an such the increase prescriptions VASCEPA, to in of are increase number basis an of also year-over-year. increases and growth number to prescribing However, contribute in
pay patient's the plan insurance patient The for deductible insurance amount and amount cards, is the good. is covered cards make The not of VASCEPA VASCEPA. players to Amarin plan out by available is can size have The which non-government tier patient copay deductible pocket continues deductible by on subject amounts to amount deductible, copay varies, of most two, from is broadly largely the be for insurance to VASCEPA to offset of whether of determined and the Amarin. required
in Recently, acid was form for an is study, Epanova, slightly EPA. early. thought STRENGTH mixture the DHA competition the that product older many that strongest VASCEPA containing the discontinued had could people an free announced it XX% outcome become and trial Omega fatty Epanova X
risk pure, appears the won't behind products indication it the STRENGTH. of statin examples indication include dietary on cardiovascular of and based are prescription details FDA. studies reduce adverse clear reduction termination be supplement niacin, yet list study that prescription of pursuing is is Epanova cardiovascular that joins Earlier that AstraZeneca top this and public, failed the in cardiovascular high-risk While VASCEPA by stable long on not for a only outcome Only events proven patients, Xs. therapy. VASCEPA DHA fibrates, containing proven to major a Omega
STRENGTH fatty and may in effects acids We fatty further trial. look forward from to that of esterified into study the learning helpful Data results more and between insights about the and differences acids. provide free EPA DHA, the between
is On lowering to that triglyceride offset the the of may which about further surface, positive the has in unique DHA termination beyond questions of such the study and effects supports adds further stable EPA. and impact and growing pure EPA ways multi-factorial
multi-year heightening potential and fatty research field. established regarding of with with information future testing It differences likely also reduction products testing risk this whether requirements compared short-term fatty clinical questions These to acids. effectiveness about the competitive free chronic for VASCEPA proven increase raises provides cardiovascular reliable to esterified in acids bar while high are uncertainties use a together by of
I doubt, VASCEPA. EPA to ethyl I The that or reminder degrades refer shown proven if EPA, fragile. to heat icosapent for esterified damaged of form only stable by, delivered EPA It that reference and marketed effective. be by to pure and The effects easily EPA when as VASCEPA to avoidance is am is oxygen. of has are stable example, is as clinical stable as to For referring be exposed to effective, pure and oxidized and not been a
as National their such guidelines to there joined and cardiovascular levels. American guidelines, as Endocrinologists the appropriate ethyl to Association, get Cardiology stands Recently, to icosapent European societies other of with don't societies alone Lipid profiles medical lower of Association VASCEPA of Diabetes Association. no for and their guidelines icosapent These statin appreciate medical therapy therapy. beyond Society patients substitute that disease American to added use their in Clinical medical They the recommended ethyl is patients risk in if current the a
the of expanding beyond and HLS the Therapeutics, from to supporting of other to lowering failed Internationally, guidelines HLS China a partner, effects VASCEPA. started is lower. we have triglyceride a to Health triglyceride provided our starting work Canada, in in selling from and team sell end and at agents, community approval that Canada, VASCEPA in be Middle what XXXX, very outcomes that and sales advance the to Canada. go societies to than VASCEPA, all VASCEPA market phased launch with uniquely existing continue In medical commercial recently there. the partners our core East, likely VASCEPA appreciate particular, show with to these
completion clinical Our before Eddingpharm, of the its trial anticipated XXXX. progressing partner with with in China, is end
We to are they indication European for as it of EMA, submitted the day EMA, delay that application as we and trial that for from additional to a expected of any not risk or and are is contains reduction information, the The of so VASCEPA cardiovascular centralized anticipate Medicines closest start corona our in is and for March questions accepted far told XXXX. as do virus. at European review. The for by announced approval filing was people We near proceeded December marketing who request which European ongoing because XXX letter Agency end process the completion has expected.
and in reduction. to are in an pursued we Canada, Europe, risk what indication was seeking approved for Similar cardiovascular
use decision patent now seek available years relating XX lowering exclusivity extend to seeking. cardiovascular in with years Europe. reduction in Canada indication XX in are VASCEPA to the protection risk Our product regulatory not new a for in anticipate We for of approval for we preserved beyond triglyceride to has Europe
interest VASCEPA capable of commercial European expressions its from Europe multiple for could to Amarin While players. been robust rights initial and have launch in VASCEPA established on own, marketing
been intend to are there we expectation the steps States that for If VASCEPA increase exploration in European by and EMA approval United initial deferring we to discussed time of Europe preparations Europe. the of and XXXX complete attention in will launch receive interest. in early in we underway, at VASCEPA from in the prior such no our that Agency our well review for commercialization for opportunities However, investor on marketing more reasons surprises sales from have late commence with Medicines communications, the VASCEPA
more cardiovascular currently as added EU than deaths In each strokes need This for million approximately approximately year XX living disease beyond in numbers people in therapy care world. million of is of in cardiovascular are disease such cases Europe, preventative events, large number in new Europe is on from Cardiovascular X.X throughout cardiovascular disease. XX very with there growing The each resulting cardiovascular heart with and it is of disease. million available top countries. Europe, results large year attacks debilitating as the
cardiovascular and likely European estimated Society expensive European to Europe for the annually. with annual results €XX disease ethyl. currently VASCEPA, with Cardiology contributed Europe Caring exceed the combined Numerous data, the improve patients. urging spending guidelines by issued for in medical for billion These are use of to clinical approval with the in Society care recommending them of icosapent key help to Europe in opinion Atherosclerosis their VASCEPA leaders is of
XXth. of are Amarin's litigation in companies, expected publicly patent be was completed docket you on on aware to available trial the portion Post-trial are likely respect January. generic the briefs late ongoing court February the that to With pharmaceutical litigation with
decision this this on regarding expressed, provide is As commentary March. litigation. proceedings, the plan matter court's not near ongoing details the expected end to previously on Based does of court of Amarin
setback we support uphold under we that the deserve and leading commercial Amarin that courts patient prevail In be for my ensure pharmaceutical further not of patents expanded considerable Amarin's benefit promotion it Such plans if this millions of otherwise to retains education development will law. believe Amarin's exclusivity exclusivity, the use to litigation. and patients. in care which do and a assume the would our we view, at-risk
should arguments of the believe the began, we’ve The conclude persuasive patents risk U. our in and convinced courts and similarly. prevail. the while we any should litigation, believe As litigation is office are our legal described before there that appropriateness that S. was patent of we
many has areas made year two, the ligitation. competition successfully there of A in and of the us VASCEPA end considerable four ago, of concern the getting Three expanded results investors; just of an In be respects, progress from to approval FDA financial Epanova; the we're end past expressed Amarin one, primary started. lable; of resources; were year. three, scheduled addressed of been these results of soon. of four, litigation addressed accuracy have four to our with by court,
the will litigation proceedings, regard we court update the of on court's expected our the based to end published March. is decision with matter stated, the After by end stakeholders previously near is court, on decision As this litigation. of
now Mike will to Kalb. Mike? I turn over discussion the
